For more NACDS Annual 2024 show coverage, visit:
Prioritizing Lower-Priced Biosimilar Medications
Legacy PBM business models are fundamentally misaligned with the needs and interests of plan sponsors and their members.
Will PBMs stick with their old business model, which maximizes drug rebates at the expense of plan sponsors and their members, or will they embrace the value-driven approach that puts customers and patients first?
More Blog Posts in This Series
4/25/2024
Challenges for Pharmacy in 2024
Pressures mount for the industry in wake of financial, operational and regulatory pressures.
4/2/2024
Viewpoint: Would fewer doors strengthen pharmacy?
John Kenlon, senior vice president and publisher of Drug Store News, looks at the ideal supply of pharmacies and profitable reimbursement levels.
1/9/2024
Here’s to our local heroes: America’s pharmacists
Filling healthcare gaps with pharmacists is both necessary and urgent to ensure people have access to the services they need.